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Abstract 
Artificial intelligence (AI) using machine learning techniques will change healthcare as we know 
it. While healthcare AI applications are currently trailing behind popular AI applications, such as 
personalised web-based advertising, the pace of research and deployment is picking up and 
about to become disruptive. Overcoming challenges such as patient and public support, 
transparency over the legal basis for healthcare data use, privacy preservation, technical 
challenges related to accessing large-scale data from healthcare systems not designed for Big 
Data analysis, and deployment of AI in routine clinical practice will be crucial. Cardiac imaging 
and imaging of other body parts is likely to be at the frontier for the development of 
applications as pattern recognition and machine learning are a significant strength of AI with 
practical links to image processing. Many opportunities in cardiac imaging exist where AI will 
impact patients, medical staff, hospitals, commissioners and thus, the entire healthcare system. 
This perspective article will outline our vision for AI in cardiac imaging with examples of 
potential applications, challenges and some lessons learnt in recent years. 
 
Introduction 
It is almost impossible in modern society to avoid exposure to artificial intelligence (AI) 
solutions such as facial recognition, speech recognition, spam filters, chatbots and personalised 
web-based advertising. While healthcare AI applications are trailing behind these widely used 
tools, AI and machine learning in healthcare research is accelerating and about to change 
healthcare as we know it. 
The terms AI, machine learning (ML) and deep learning (DL) are often used interchangeably but 
are essentially hierarchical. AI is the overarching concept aiming to develop computers with 
human intelligence. ML methods provides a set of tools to achieve AI and includes supervised, 
unsupervised and reinforcement learning. DL is a supervised ML technique using neural 
networks which are used frequently in novel AI solutions. 
Through AI clinical pathways will be streamlined and transformed. Opportunities exist at every 
step, from patient identification and referral to scheduling, image acquisition and 
reconstruction, automating analysis of images and image interpretation, report writing and 
communicating the obtained information to the referring physician with clinical decision 
support systems. There are a number of reasons why AI in healthcare has not been the first 
   
 
   
 
area of focus, including data availability, privacy-concerns, and lack of firm and universally 
agreed upon legal basis for use of data, to name just a few. However, despite these limitations 
there is substantial untapped potential to transform patient pathways and improve the value of 
healthcare. Embedding the best AI solutions into clinical practice will likely result from public-
private partnerships. 
 
Success stories to date 
AI in cardiac imaging is a fast-moving field and is already starting to have an impact clinically. 
Two factors contributed significantly to the fact that recently a sizeable number of approaches 
to cardiovascular magnetic resonance (CMR) segmentation algorithms have been published (1–
10). Firstly, the National Institute of Health (NIH) initiated the Second Annual Data Science Bowl 
(2015) on Kaggle, which challenged participants to create an algorithm to measure end-systolic 
and end-diastolic volumes in cardiac MRIs automatically. Secondly, it was only just over two 
years ago at the 2017 Society for Cardiovascular Magnetic Resonance Annual Scientific Session 
during which Robert (Bob) Balaban, NIH, challenged the CMR community during his visionary 
keynote lecture “What’s Next To come in CMR” with his slide “Drawing circles. This has to 
stop.” Of note, companies increasingly offer AI based automated segmentation solutions, with 
Arterys having received FDA approval for heart MRI interpretation in January 2017 (11).  
 
However, AI applications emerge in all non-invasive cardiac imaging modalities and not just 
CMR covering a range of applications from image classification, image reconstruction, 
automation in segmentation and quantification and guiding diagnosis and prognosis. Recently, 
these have been reviewed comprehensively (12, 13). Cui and colleagues developed an AI 
approach to improve image reconstruction for dynamic PET (14). Deep learning solutions to 
automate calcium scoring from CT attenuation correction in patients following Rb-PET/CT is 
promising. There was good agreement for the classification into 5 categories from very low to 
very high calcium scores (Cohen’s kappa up to 0.89) (15). Deep learning approaches have also 
been shown to diagnose obstructive coronary artery disease more accurately compared to 
conventional methods using myocardial perfusion imaging (MPI) (16). For SPECT-MPI, a 
machine learning approach including clinical information was found capable of superior MACE 
prediction compared to machine learning approaches alone or conventional clinical assessment 
of SPECT-MPI (16, 17).  
 
A recent study in over 14,000 echocardiograms showed promise for AI applications to 
automatically classify image orientation, perform image segmentation and assign a diagnosis 
(18). Detection of wall motion abnormalities on echocardiography requires experience and can 
thus suffer from observer variability. AI solutions are emerging which have good accuracy for 
this task (19). Furthermore, in the Multi-Ethnic Study of Atherosclerosis (MESA), Ambale-
Venkatesh and colleagues demonstrated the potential of machine learning to develop more 
accurate cardiovascular risk prediction tools when supplied with clinical information and data 
from deep cardiac imaging phenotyping, such as CMR, cardiac CT and carotid ultrasound (20). 
 
   
 
   
 
Clinical opportunities with AI in cardiac imaging 
Despite these success stories of use of AI in cardiac imaging, we are only at the beginning of a 
journey. Imaging (including cardiac) is likely to be at the frontier for the development of AI 
applications as pattern recognition is a significant strength of AI. AI solutions in cardiac imaging 
will impact the entire healthcare system. This will happen through the range of beneficiaries 
including patients, medical staff, hospitals and commissioners. One way to structure these 
opportunities is to consider the patient pathway involving non-invasive cardiac imaging. It does 
not take much imagination to identify tasks that AI may tackle efficiently along the entire 
pathway from patient identification and referral to informing patient management based on 
the cardiac imaging report. We believe AI will tackle well-circumscribed tasks initially, but the 
ultimate aim should be to integrate the separate tasks into one smooth and efficient pipeline. 
This integration of tasks is an aim of the CMR programme “SmartHeart: Next-generation 
cardiovascular healthcare via integrated image acquisition, reconstruction, analysis and 
learning” funded by the Engineering and Physical Sciences Research Council (21).  
We list examples of AI opportunities along the clinical pathway in non-invasive imaging in 
Figure 1. 
 
Research opportunities with AI in cardiac imaging 
Development of clinically robust AI algorithms demands large, high-quality datasets. Slomka 
and colleagues set up a large-scale powerful resource for AI development which may serve as 
template for other non-invasive imaging modalities: REFINE SPECT – the Registry of Fast 
Myocardial Perfusion Imaging with NExt generation SPECT (22). REFINE SPECT is a multi-centre 
registry with sites contributing nuclear images alongside clinical data in a framework that 
ensures appropriate de-identification (pseudo-anonymisation) with standardised analysis of all 
images and follow up for MACE. This collaborative registry will aid development and validation 
of AI tools for automated diagnosis and risk stratification. 
 
Meta-analyses combine data from multiple studies aiming to summarise and identify common 
effects or find explanations for variation in the effects observed. Individual participant data 
meta-analysis compared to study level meta-analysis has many advantages, as discussed in 
detail by Riley and colleagues (23). For cardiac imaging, the attraction is that heterogeneity 
through different approaches to image analysis can be removed. Time-consuming image 
analysis can now be tackled using AI solutions and opens an opportunity to consider such 
individual participant meta-analyses. One such application could be the generation of new 
reference values for common clinical measures, such as LV and RV volumes and mass, with 
larger datasets. This may allow more precision but also the ability to create much more detailed 
references ranges, e.g. between ethnicities, age or sex. Another application maybe randomised 
controlled trials that use cardiac imaging as endpoints which could also be re-analysed to 
summarise findings across studies. 
 
Radiomics provide a novel approach to image interpretation, enabling derivation of a multitude 
of quantifiable metrics related to e.g. signal intensity, texture, shape. Radiomics approaches 
have been promising in cancer diagnosis and risk stratification. Cardiac radiomics are in their 
   
 
   
 
infancy with significant potential impact. Some of these measures are beyond what can be 
appreciated visually by human experts. In cardiac imaging radiomics may help get closer to 
personalised medicine through improved diagnosis and risk stratification. A review for cardiac 
CT radiomics provides an outline of the methodology and opportunities but is applicable to all 
cardiac imaging modalities (24). 
 
Research is also required to demonstrate the real-world benefit in terms of clinical 
effectiveness using e.g. quasi-experimental study designs. Furthermore, economic evaluations 
are required to demonstrate the cost-effectiveness of AI solutions compared to standard of 
care. 
 
Challenges 
Overcoming challenges such as patient and public support, transparency over the legal basis for 
healthcare data use, privacy preservation, technical challenges related to accessing large-scale, 
expertly labelled data from healthcare systems not designed for Big Data analysis, and 
deployment of AI in routine clinical practice will be critical. These challenges are substantial and 
only if addressed pro-actively will not lead to substantial slowing down of the AI developments 
in cardiac imaging. 
 
Future Advocacy, an AI think tank in the UK, has identified challenges of AI and healthcare in a 
Wellcome Trust commissioned white paper (25). They highlighted that we cannot simply 
assume patients and the public are happy for healthcare data to be shared and used for AI 
development. Future Advocacy tasked YouGov to explore patient and public perception. 
YouGov in 2017 used a representative online survey amongst 2,108 UK adults. Responses were 
surprising to the question "How comfortable would you be with your personal medical 
information being used to improve healthcare?": 49% were uncomfortable with the idea and 
11% did not know (25). These findings underscore the need to educate all stakeholders on the 
potential benefits and risks of using AI techniques. Nundy and colleagues reflected on how trust 
between physicians and patients can be enhanced in this era of digital innovation and artificial 
intelligence. AI in healthcare has the potential to both positively and negatively influence the 
three components key to trust: competence, motive and transparency. One practical 
recommendation when implementing AI tools according to Nundy and colleagues is to strive 
towards acknowledging the source of the data, qualify AI-based recommendations, and be 
explainable (26). 
 
Examples of AI have emerged demonstrating the risk of introducing biases into the AI 
algorithms – from discrimination (27) to adding or removing evidence of medical conditions 
from medical scans (28). One could imagine if cardiac imaging AI algorithms get trained only on 
the wealthy population’s images that algorithms may then not generalise well to the poor 
population. This introduces inequalities in health and healthcare. The opposite may also be true 
– through standardisation and availability of AI tools supporting healthcare in poorer parts of 
the world health, inequalities may be reduced. 
 
   
 
   
 
Lack of interpretability (“black box”) of the AI solution is not such a concern for the 
segmentation problem in cardiac imaging. The physician does not need to understand how the 
segmentation was derived by the AI algorithm as she/he can and should check for accuracy and 
if needed modify the contours. The responsibility firmly remains with the physician. However, 
AI tools that predict risk or suggest differential diagnoses may be problematic due to lack of 
explainability. Removing black boxes in AI is an area of active research to reduce this 
uncertainty of how decisions are reached – this was the topic of an entire workshop at the 
Medical Image Computing and Computer Assisted Intervention conference (MICCAI) 2018. 
Another important question is where the legal responsibility lies when the AI tool makes 
harmful recommendations. Is it the company providing the AI tool, the physician seeing the 
patient, the researchers who labelled the training and testing datasets? 
 
There are further challenges and questions related to AI in healthcare and cardiac imaging. In 
the regulation of AI solutions, the evidence required differs between regulators. How should 
regulators handle the need to update the AI algorithms over time. How should AI algorithms be 
checked for reproducibility? How can AI algorithms for the same problem be best compared to 
identify the optimal solution? Who should be certifying the suitability of AI algorithms for 
imaging? The Data Science Institute of the American College of Radiology offers the “Certify-AI” 
service for this purpose to benchmark AI solutions before going to the regulators (29, 30). 
 
There is also little guidance currently on how much data is enough data for developing specific 
AI tools. As annotation of imaging is time-consuming and expensive, the aim should be to use 
the minimum data to develop and test robust AI tools. Should the data for training be 
heterogenous or representative? What is the best trade-off between accuracy and 
generalisability of the AI tools? 
 
One of the concerns of the public may be related to the sharing of healthcare data with 
commercial partners for the development of AI tools. Should sharing with commercial partners 
require prospective consent from patients or opt-out solutions? A key will be to work with 
patients and the public to build and maintain trust to find practical and acceptable solutions. 
 
If patients withdraw consent for the use of their data in the development of AI algorithms but 
also from the input it had in developed AI tools, this is a challenge. It is hard to remove single 
patient datasets from the trained algorithm once it is there, so there is some “non-reversibility” 
challenge. Some ethicists have argued that since patients do not pay the true price of 
healthcare, it is not immoral to suggest there is some burden on them to contribute data if this 
can improve the efficiency of the healthcare system (this operates from the principle that 
healthcare data are a public good and are neither 100% the property of the patient nor the 
researcher/institute) (31).  
 
Lessons learnt and key messages 
• Multidisciplinarity is key to success and in an iterative fashion - handing over 
data/annotated data to the data scientist is not sufficient as a multi-disciplinary approach. 
   
 
   
 
• We need to train imagers to become data experts/AI enablers and AI experts to 
understand the clinical needs/challenges/risks. 
• We need to engage to find solutions of getting the balance right for data access guarding 
issues related to privacy, ethics and commercial partnerships. 
• Importance of perception. As a community we need to take public and patients and our 
profession with us on this journey. 
• AI is not the solution to everything in cardiac imaging - thus we still need imagers in 
years to come. 
 
Vision for AI and cardiac imaging 
Cardiac imaging will benefit from integration of various AI solutions. Physicians will then be able 
to focus on tasks best done by human intelligence without being distracted by tasks that can be 
automated. This may lead to higher physician job satisfaction, improved patient-physician 
relationships, improved quality of healthcare delivery and improved equality of health and 
access to healthcare whilst limiting the unsustainable rise in healthcare expenditure in an aging 
population. 
 
Conclusion 
This era of AI in healthcare is providing disruptive opportunities to transform how we provide 
non-invasive cardiac imaging in clinical pathways. However, many challenges remain and need 
to be proactively addressed to keep patients and the public open to the development and 
introduction of AI solutions. The potential is exciting to make our healthcare systems better in 
terms of quality, equality and cost-effectiveness. 
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Figure legends 
Figure 1: Examples of AI opportunities using AI along cardiac imaging clinical pathway that may 
increase the clinical value of healthcare delivery 
